taletrectinib 200 MG Oral Capsule
- RxCUI
- 2716925
- RxNorm name
- taletrectinib 200 MG Oral Capsule
- Display name
- taletrectinib 200 MG Oral Capsule
- Full name
- taletrectinib 200 MG Oral Capsule
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:58
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| IBTROZI | TALETRECTINIB | Nuvation Bio Inc. | 51ac8e52-3269-4102-8dc8-dba22d82128c | 2026-09-21 | Warnings, Adverse reactions | 2716925 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 51ac8e52-3269-4102-8dc8-dba22d82128c | taletrectinib 200 MG Oral Capsule [PSN] · taletrectinib 200 MG Oral Capsule [SCD] · taletrectinib 200 MG (as taletrectinib adipate 272 MG) Oral Capsule [SY] | 3 | 4 | These highlights do not include all the information needed to use IBTROZI safely and effectively. See full prescribing information for IBTROZI. IBTROZI ® (taletrectinib) capsules, for oral use Initial U.S. Approval: 2025 | 20260323 |